Home > Expanded Access > Expanded Access to Provide LOXO-195 for the Treatment of Cancers With a NTRK Gene Fusion

Loxo Oncology, Inc.

Expanded Access to Provide LOXO-195 for the Treatment of Cancers With a NTRK Gene Fusion

Official Title: 
Expanded Access to Provide LOXO-195 for the Treatment of Cancers With a NTRK Gene Fusion
Brief Summary: 
LOXO-195 expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion who are ineligible for an ongoing LOXO-195 clinical trial or have other considerations that prevent access to LOXO-195 through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers, including blood cancers, with a NTRK gene fusion who have previously received TRK inhibitor therapy
Available
EA Type
Individual Patients
Cancer, Neurotrophic Tyrosine Kinase, Receptor-related Proteins

Drug: LOXO-195
Open-label expanded access

Eligibility Criteria: 

Inclusion Criteria:

- Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion

- Previous treatment with a kinase inhibitor with known activity on TRK inhibition

- Unable to participate in an ongoing LOXO-195 clinical trial

- Willing and able to provide written, signed informed consent

- Medically suitable for treatment with LOXO-195

Exclusion Criteria:

- Currently enrolled in an ongoing clinical study with a TRK inhibitor

Eligibility Gender: 
All
Contacts: 

Patient Advocacy
1-855-NTRK-123
clinicaltrials@loxooncology.com

Nora Ku, MD
Study Director
Loxo Oncology

Michael Cox, PharmD, MHSc, BCOP
Study Director
Loxo Oncology

Loxo Oncology, Inc.
Bayer
EA Number: 
MeSH Terms: 
9-Fluoro-15-methyl-2,11,16,20,21,24-hexaazapentacyclo(16.5.2.02,6.07,12.021,25)pentacosa-1(24),7,9,11,18(25),19,22-heptaen-17-one
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.